Ambanna Yappalparvi, Mahalaqua Nazli Khatib, Ashok Kumar Balaraman, M M Rekha, Mandeep Kaur, Girish Chandra Sharma, Puneet Sudan, K Satyam Naidu, Rajesh Singh, Sonam Ramashankar, Karan Khati, Sanjay Singh Chauhan, Lokesh Verma, Amritpal Sidhu, Rachana Mehta, Renu Sah, Abhay M Gaidhane, Muhammed Shabil, Joseph Clement Chipeta, Ganesh Bushi
{"title":"Prevalence of Mpox vaccine acceptance and hesitancy among people living with HIV: a comprehensive systematic review and meta-analysis.","authors":"Ambanna Yappalparvi, Mahalaqua Nazli Khatib, Ashok Kumar Balaraman, M M Rekha, Mandeep Kaur, Girish Chandra Sharma, Puneet Sudan, K Satyam Naidu, Rajesh Singh, Sonam Ramashankar, Karan Khati, Sanjay Singh Chauhan, Lokesh Verma, Amritpal Sidhu, Rachana Mehta, Renu Sah, Abhay M Gaidhane, Muhammed Shabil, Joseph Clement Chipeta, Ganesh Bushi","doi":"10.1186/s12981-025-00726-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vaccine acceptance among People Living with HIV (PLWH) is crucial for managing and mitigating the spread of infectious diseases, including Mpox. This systematic review and meta-analysis assess the rate of vaccine acceptance for Mpox among PLWH and identify factors influencing these rates.</p><p><strong>Methods: </strong>We searched major databases including PubMed, Embase, and Web of Science up to 30 August 2024 for observational studies involving PLWH that reported on mpox vaccine acceptance rates. A random-effects model was employed for the meta-analysis, utilizing R software version 4.4. Heterogeneity among the studies was quantified using the I² statistic, and the methodological quality of each study was assessed using a modified version of the Newcastle-Ottawa Scale.</p><p><strong>Results: </strong>Out of 1,123 articles identified, 17 studies met the inclusion criteria and included 7,248 participants. The pooled estimate of the Mpox vaccine acceptance rate was 61.1% (95% CI: 44.2-75.7%), with high heterogeneity (I² = 99%). Additionally, a pooled vaccine hesitancy prevalence was 13.2%, (95% CI: 2.4-48.6%), reflecting substantial variability and had high heterogeneity (I² = 98%).</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis reveal moderate Mpox vaccine acceptance and considerable hesitancy among PLWH. To further increase vaccine uptake and address any remaining hesitancy in this at-risk population, targeted public health strategies and ongoing research are necessary. Strengthening vaccine acceptance is critical to safeguarding PLWH against emerging infectious diseases such as Mpox.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":"31"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889782/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12981-025-00726-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Vaccine acceptance among People Living with HIV (PLWH) is crucial for managing and mitigating the spread of infectious diseases, including Mpox. This systematic review and meta-analysis assess the rate of vaccine acceptance for Mpox among PLWH and identify factors influencing these rates.
Methods: We searched major databases including PubMed, Embase, and Web of Science up to 30 August 2024 for observational studies involving PLWH that reported on mpox vaccine acceptance rates. A random-effects model was employed for the meta-analysis, utilizing R software version 4.4. Heterogeneity among the studies was quantified using the I² statistic, and the methodological quality of each study was assessed using a modified version of the Newcastle-Ottawa Scale.
Results: Out of 1,123 articles identified, 17 studies met the inclusion criteria and included 7,248 participants. The pooled estimate of the Mpox vaccine acceptance rate was 61.1% (95% CI: 44.2-75.7%), with high heterogeneity (I² = 99%). Additionally, a pooled vaccine hesitancy prevalence was 13.2%, (95% CI: 2.4-48.6%), reflecting substantial variability and had high heterogeneity (I² = 98%).
Conclusion: This systematic review and meta-analysis reveal moderate Mpox vaccine acceptance and considerable hesitancy among PLWH. To further increase vaccine uptake and address any remaining hesitancy in this at-risk population, targeted public health strategies and ongoing research are necessary. Strengthening vaccine acceptance is critical to safeguarding PLWH against emerging infectious diseases such as Mpox.
期刊介绍：
AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
